Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* both sexes;aged\>18 years;~* suffering from different types of malignancies(lung, breast,gastric,colon- rectum,pancreatic,ovarian,head and neck cancer)undergoing systemic chemotherapy,~* having signed Informed Consent prior to initiation of any study procedure.~EXCLUSION CRITERIA:~* adjuvant and neo-adjuvant chemotherapy;~* objectively confirmed venous or arterial thromboembolism in the last three months;~* antithrombotic treatment for other indications;~* life expectancy of less than 3 months;~* Performance Status\>2(ECOG);~* active bleeding or bleedings in the last four weeks requiring hospitalization,transfusion or surgical intervention;~* bleeding diathesis(prothrombin time\<70% or activated partial thromboplastin time ratio\>1.3),or platelet count\<50x10\^9/L;~* cerebrovascular hemorrhage in the last six months;~* known active gastric or duodenal ulcer;~* known cerebral metastasis;~* cerebral aneurysm;~* III-IV grade diabetic retinopathy;~* severe and uncontrolled hypertension(systolic blood pressure\>180 mmHg or diastolic blood pressure\>110 mmHg);~* chronic atrial fibrillation;~* acute endocarditis;~* acute pancreatitis;~* known hypersensitivity to unfractionated heparin or LMWH;~* previous occurrence of heparin-induced thrombocytopenia;~* renal impairment (dependent on dialysis or creatinine higher than 2.5mg%);~* liver insufficiency (alanine aminotransferase,aspartate aminotransferase,alkaline phosphatase levels\>3 times the upper limit of the normal ranges and/or total bilirubin \>3.0 mg/ml);~* pregnancy or childbearing potential without adequate contraception;~* treatment with other investigational drugs or patient inclusion in other clinical trials;~* patients who are unable to fulfill the study requirements in terms of visits/compliance to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- saline solution (Type: PLACEBO_COMPARATOR): Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
- nadroparin calcium (Type: EXPERIMENTAL): Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).